Journal of Maxillofacial and Oral Surgery

, Volume 16, Issue 1, pp 65–70 | Cite as

Immunohistochemistry of Five Molecular Markers for Typing and Management of Ameloblastomas: A Retrospective Analysis of 40 Cases

  • Thasvir Singh
  • Arun Chandu
  • John Clement
  • Christopher Angel
Research Paper

Abstract

Purpose

The aims of this study are to elucidate if molecular markers can be used to differentiate between the two main types of ameloblastoma (unicystic and solid/multicystic), and to determine whether a biologically ‘less-aggressive’ subtype exists.

Methods

A retrospective analysis of 33 solid/multicystic ameloblastomas and six unicystic ameloblastomas was completed using immunohistochemistry for five molecular markers: P16, P53, MMP-9, Survivin, and Ki-67. Tumors were graded as either negative or positive (mild, moderate, strong), and the results were related to both ameloblastoma subtypes and outcomes following treatment.

Results

Unicystic ameloblastomas were more likely to test strongly positive for P53 than solid/multicystic ameloblastomas (p < 0.05), whereas the latter were more likely to be negative for Survivin (p < 0.05). Solid/multicystic and Type 3 unicystic ameloblastomas that were positive for P16, but also negative for MMP-9 and Survivin, were less likely to recur than all other tumors (p < 0.05). The proliferation index of an ameloblastic carcinoma (11 %) was shown to be higher than benign ameloblastomas (4.5 %).

Conclusions

Immunohistochemistry can be valuable in lesions where histological sub-typing of an ameloblastoma is unclear. A biologically ‘less-aggressive’ subtype may exist, and hence further research into this area is required.

Keywords

P16 Markers Diagnosis Outcome Ameloblastoma 

References

  1. 1.
    Kumamoto H (2006) molecular pathology of odontogenic. J Oral Pathol Med 35:65–74CrossRefPubMedGoogle Scholar
  2. 2.
    Li T, Wu Y, Yu S, Yu G (2000) Unicystic ameloblastoma: a clinicopathologic study of 33 Chinese patients. Am J Surg Pathol 24(10):1385–1392CrossRefPubMedGoogle Scholar
  3. 3.
    Singh TSC (2009) Ameloblastoma: report on two cases and review of the literature. N Z Dent J 105(1):13–17PubMedGoogle Scholar
  4. 4.
    Gardner D, Heikinheimo K, Shear M, Philipsen H, Coleman H (2005) Ameloblastoma. In: Barnes L, Eveson JW, Reichart P, Sidransky D (eds) World Health Organization classification of tumours: pathology and genetics of head and neck tumours. International Agency for Research on Cancer, LyonGoogle Scholar
  5. 5.
    Artese L, Lessi G, Piattelli A, Rubini C, Goteri G, Pernotti V, Piccirilli M, Carinci F (2008) p16 expression in odontogenic cysts. Dent Res J 5(2):61–64Google Scholar
  6. 6.
    Artese L, Piattelli A, Rubini C, Goteri G, Pernotti V, Lessi G, Piccirilli M, Carinci F (2008) p16 expression and odontogenic tumours. Tumori 94:718–723PubMedGoogle Scholar
  7. 7.
    Mendelsohn AH, Lai CK, Shintaku IP, Elashoff DA, Dubinett SM, Abemayor E, St John MA (2010) Histopathologic findings of HPV and p16 positive HNSCC. Laryngoscope 120(9):1788–1794. doi:10.1002/lary.21044 CrossRefPubMedGoogle Scholar
  8. 8.
    Yamamoto T, Tanigawa N (2001) The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsc 34(4):207–212. doi:10.1007/s007950100017 CrossRefPubMedGoogle Scholar
  9. 9.
    Kumamoto H, Ooya K (2004) Expression of survivin and X chromosome-linked inhibitor of apoptosis protein in ameloblastomas. Virchows Arch 444(2):164–170. doi:10.1007/s00428-003-0941-9 CrossRefPubMedGoogle Scholar
  10. 10.
    Kumamoto HIT, Ohki K, Takahashi N, Ooya K (2004) p53 gene status and expression of p53, MDM2, and p14ARF proteins in ameloblastomas. J Oral Pathol Med 33:292–299CrossRefPubMedGoogle Scholar
  11. 11.
    Sharifi-Sistani N, Zartab H, Babakoohi S, Saghravanian N, Jamshidi S, Esmaili H, Mohtasham N, Zamanzadeh M, Abbaszadeh-Bidokhty H (2011) Immunohistochemical comparison of the expression of p53 and MDM2 proteins in ameloblastomas and keratocystic odontogenic tumors. J Craniofac Surg 22(5):1652–1656. doi:10.1097/SCS.0b013e31823188e9 CrossRefPubMedGoogle Scholar
  12. 12.
    Gadbail AR, Chaudhary M, Patil S, Gawande M (2009) Actual Proliferating Index and p53 protein expression as prognostic marker in odontogenic cysts. Oral Dis 15(7):490–498. doi:10.1111/j.1601-0825.2009.01590.x CrossRefPubMedGoogle Scholar
  13. 13.
    Gurgel CA, Ramos EA, Azevedo RA, Sarmento VA, da Silva Carvalho AM, dos Santos JN (2008) Expression of Ki-67, p53 and p63 proteins in keratocyst odontogenic tumours: an immunohistochemical study. J Mol Histol 39(3):311–316. doi:10.1007/s10735-008-9167-0 CrossRefPubMedGoogle Scholar
  14. 14.
    Salehinejad JZ-MR, Saghafi S, Jafarian AH, Ghazi N, Rajaei AR, Marouzi P (2011) Immunohistochemical detection of p53 and pCNA in ameloblastoma and adenomatoid odontogenic tumor. J Oral Sci 53(2):213–217CrossRefPubMedGoogle Scholar
  15. 15.
    Chaturvedi AK (2012) Epidemiology and clinical aspects of HPV in head and neck cancers. Head Neck Pathol 6(Suppl 1):S16–S24. doi:10.1007/s12105-012-0377-0 CrossRefPubMedGoogle Scholar
  16. 16.
    Ang K, Sturgis E (2012) Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. Semin Radiat Oncol 22(2):128–142CrossRefPubMedGoogle Scholar
  17. 17.
    Lewis JS Jr, Thorstad WL, Chernock RD, Haughey BH, Yip JH, Zhang Q, El-Mofty SK (2010) p16 positive oropharyngeal squamous cell carcinoma:an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol 34(8):1088–1096. doi:10.1097/PAS.0b013e3181e84652 CrossRefPubMedGoogle Scholar
  18. 18.
    Natarajan E, Saeb M, Crum CP, Woo SB, McKee PH, Rheinwald JG (2003) Co-expression of p16(INK4A) and laminin 5 gamma2 by microinvasive and superficial squamous cell carcinomas in vivo and by migrating wound and senescent keratinocytes in culture. Am J Pathol 163(2):477–491CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kobayashi S, Shirasawa H, Sashiyama H, Kawahira H, Kaneko K, Asano T, Ochiai T (1999) P16INK4a expression adenovirus vector to suppress pancreas cancer cell proliferation. Clin Cancer Res 5(12):4182–4185PubMedGoogle Scholar
  20. 20.
    Kumamoto H, Kimi K, Ooya K (2001) Detection of cell cycle-related factors in ameloblastomas. J Oral Pathol Med 30:309–315CrossRefPubMedGoogle Scholar
  21. 21.
    Zhong Y, Guo W, Wang L, Chen X (2011) Molecular markers of tumor invasiveness in ameloblastoma: an update. Ann Maxillofac Surg 1(2):145. doi:10.4103/2231-0746.92780 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Ribeiro BF, Iglesias DP, Nascimento GJ, Galvao HC, Medeiros AM, Freitas RA (2009) Immunoexpression of MMPs-1, -2, and -9 in ameloblastoma and odontogenic adenomatoid tumor. Oral Dis 15(7):472–477. doi:10.1111/j.1601-0825.2009.01575.x CrossRefPubMedGoogle Scholar
  23. 23.
    Pinheiro JJVFV, Moretti AIS, Jorge AG, Jaeger RG (2004) Local invasiveness of ameloblastoma. Role played by matrix metalloproteinases and proliferative activity. Histopathology 45:65–72CrossRefPubMedGoogle Scholar
  24. 24.
    Henriques AC, Vasconcelos MG, Galvao HC, de Souza LB, de Almeida Freitas R (2011) Comparative analysis of the immunohistochemical expression of collagen IV, MMP-9, and TIMP-2 in odontogenic cysts and tumors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112(4):468–475. doi:10.1016/j.tripleo.2011.05.033 CrossRefPubMedGoogle Scholar
  25. 25.
    Rosenthal EL, Matrisian LM (2006) Matrix metalloproteases in head and neck cancer. Head Neck 28(7):639–648. doi:10.1002/hed.20365 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Kumamoto H, Yamauchi K, Yoshida M, Ooya K (2003) Immunohistochemical detection of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in ameloblastomas. J Oral Pathol Med 32:114–120CrossRefPubMedGoogle Scholar
  27. 27.
    Yoon HJ, Jo BC, Shin WJ, Cho YA, Lee JI, Hong SP, Hong SD (2011) Comparative immunohistochemical study of ameloblastoma and ameloblastic carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112(6):767–776. doi:10.1016/j.tripleo.2011.06.036 CrossRefPubMedGoogle Scholar
  28. 28.
    Zhang B, Zhang J, Huang HZ, Chen WL, Tao Q, Zeng DL, Zhang LT, Xu JH (2009) Inhibition of ameloblastoma invasion in vitro and in vivo by inhibitor of metalloproteinase-2 activity. J Oral Pathol Med 38(9):731–736. doi:10.1111/j.1600-0714.2009.00771.x CrossRefPubMedGoogle Scholar
  29. 29.
    Wang A, Zhang B, Huang H, Zhang L, Zeng D, Tao Q, Wang J, Pan C (2008) Suppression of local invasion of ameloblastoma by inhibition of matrix metalloproteinase-2 in vitro. BMC Cancer 8:182. doi:10.1186/1471-2407-8-182 CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Bologna-Molina R, Mosqueda-Taylor A, Lopez-Corella E, de Almeida OP, Carrasco-Daza D, Farfan-Morales JE, Molina-Frechero N, Damian-Matsumura P (2009) Comparative expression of syndecan-1 and Ki-67 in peripheral and desmoplastic ameloblastomas and ameloblastic carcinoma. Pathol Int 59(4):229–233. doi:10.1111/j.1440-1827.2009.02355.x CrossRefPubMedGoogle Scholar
  31. 31.
    Slootweg PJ (1995) p53 protein and Ki-67 reactivity in epithelial odontogenic lesions. An immunohistochemical study. J Oral Pathol Med 24(9):393–397CrossRefPubMedGoogle Scholar
  32. 32.
    Jaaskelainen KJK, Leivo I, Saloniemi I, Knuutila S, Heikinheimo K (2002) Cell proliferation and chromosomal changes in human ameloblastoma. Cancer Genet Cytogenet 136:31–37CrossRefPubMedGoogle Scholar
  33. 33.
    Akrish S, Buchner A, Shoshani Y, Vered M, Dayan D (2007) Ameloblastic carcinoma: report of a new case, literature review, and comparison to ameloblastoma. J Oral Maxillofac Surg 65(4):777–783. doi:10.1016/j.joms.2005.11.116 CrossRefPubMedGoogle Scholar
  34. 34.
    Bello IO, Alanen K, Slootweg PJ, Salo T (2009) Alpha-smooth muscle actin within epithelial islands is predictive of ameloblastic carcinoma. Oral Oncol 45(9):760–765. doi:10.1016/j.oraloncology.2008.11.011 CrossRefPubMedGoogle Scholar
  35. 35.
    Sandra F, Mitsuyasu T, Nakamura N, Shiratsuchi Y, Ohishi M (2001) Immunohistochemical evaluation of PCNA and Ki-67 in ameloblastoma. Oral Oncol 37(2):193–198CrossRefPubMedGoogle Scholar
  36. 36.
    Florescu A, Simionescu C, Ciurea R, Pitru A (2012) P53, Bcl-2 and Ki67 immunoexpression in follicular solid ameloblastomas. Rom J Morphol Embryol 53(1):105–109PubMedGoogle Scholar
  37. 37.
    Razavi S, Tabatabaie S, Hoseini A, Hoseini E, Khabazia A (2012) A comparative immunohistochemical study of Ki-67 and Bcl-2 expression in solid ameloblastoma and adenomatoid odontogenic tumor. Dent Res J 9(2):192–197CrossRefGoogle Scholar
  38. 38.
    Soluk Tekkesin M, Mutlu S, Olgac V (2012) Expressions of bax, bcl-2 and Ki-67 in odontogenic keratocysts (keratocystic odontogenic tumor) in comparison with ameloblastomas and radicular cysts. Turk Patoloji Derg 28(1):49–55. doi:10.5146/tjpath.2012.01097 PubMedGoogle Scholar

Copyright information

© The Association of Oral and Maxillofacial Surgeons of India 2016

Authors and Affiliations

  • Thasvir Singh
    • 1
    • 2
  • Arun Chandu
    • 2
  • John Clement
    • 2
  • Christopher Angel
    • 3
  1. 1.Oral and Maxillofacial Surgery Office C/- 2 NorthRoyal Melbourne HospitalParkvilleAustralia
  2. 2.Melbourne Dental School, Faculty of Medicine, Dentistry and Health SciencesThe University of MelbourneCarltonAustralia
  3. 3.Peter MacCallum Cancer CentreEast MelbourneAustralia

Personalised recommendations